Testing different dosing schedules of the anti-cancer drug, Lutetium-177-PSMA (Pluvicto), and its effect on patients with advanced prostate cancer

Full Title

Radioligand Efficacy Comparison by Initial PSA-Response Outcome in Metastatic CRPC with Lutetium 177Lu PSMA RLT (RECIPROCAL) (A032304) (CIRB)

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Deaglan McHugh’s office at 631-212-6320.